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Abstract
Purpose Current guidelines recommend prophylactic use of
granulocyte-colony stimulating factors (G-CSF) when febrile
neutropenia (FN) risk is greater than 20%. Advanced age is a
risk factor for FN; however, little is known about the impact of
other factors on the incidence of FN in an older population.
Patients and methods We analyzed SEER-Medicare data
(1994–2005) to develop and validate a prediction model for
hospitalization with fever, infection, or neutropenia occur-
ring after chemotherapy initiation for patients with breast,
colorectal, prostate, and lung cancer.
Results In multivariate analysis (N=58,053) independent
predictors of FN included advanced stage at diagnosis [stage
2 (OR 1.29; 95%CI: 1.09–1.53), stage 3 (1.38; 95% CI: 1.19–
1.60), and stage 4 (1.57; 95% CI: 1.35–1.83)], number of
associated comorbid conditions [one condition (1.13; 95%
CI: 1.02–1.28), two conditions (1.39; 95% CI: 1.22–1.57),
and three or more conditions (1.81; 95% CI: 1.61–2.04)],
receipt of myelosuppressive chemotherapy (1.11; 95%
CI: 0.94–1.32), and receipt of chemotherapy within 1 month
of diagnosis [1 to 3 months (0.70; 95% CI: 0.62–0.80) and
greater than 3 months (0.63; 95% CI: 0.55–0.73)].
Conclusion We created a prediction model for febrile
neutropenia with first cycle of chemotherapy in a large
population of elderly patients with common malignancies.
Keyword Elderly patients . Febrile neutropenia .
Prediction rule . SEER-Medicare dataset
Introduction
Febrile neutropenia (FN) is a major dose-limiting toxicity of
systemic chemotherapy, associated with delays in treatment,
hospitalization, higher costs [1, 2], and mortality ranging from
4% to 21% [1, 3]. Prophylactic administration of granulocyte-
colony stimulating factor (G-CSF) decreases the risk of
febrile neutropenia and infection [4, 5]. Given the significant
costs associated with G-CSF, it is neither practical nor
clinically appropriate to administer this agent to all patients
receiving chemotherapy. Rates of FN vary substantially with
different chemotherapy regimens and many commonly used
regimens have a negligible risk of FN [6–8]. American
Society of Clinical Oncology (ASCO) guidelines recommend
G-CSF prophylaxis when the risk of FN is approximately
20% or higher [6]. These guidelines also recommend primary
prophylaxis be considered in patients at increased risk due to
advanced age (>65), poor performance status, pre-existing
neutropenia, extensive prior chemotherapy, irradiation to a
significant amount of bone marrow, a history of recurrent FN,
and comorbid conditions that increase the risk of mortality
with a serious infection. Despite these recommendations,
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limited data exist on the increase in risk associated with each
of these conditions. In addition, little is known about how
these risk factors may interact in the elderly who are already
vulnerable [8].
In this study, we sought to create a clinical prediction
model for the risk of FN in the first cycle of chemotherapy in
the elderly. At a time when efforts are being made to provide
more aggressive chemotherapy for older individuals, it is
important to further identify those patients at highest risk of
complications related to neutropenia.
Methods
Data sources
We used the SEER-Medicare database, which has been
previously well-described [9]. The catchment areas (six
metropolitan areas and five states) of the SEER population,
not including the 2,000 expansion areas (Kentucky, Louisiana,
New Jersey, and California), covers about 14% of the total US
population. The SEER population is comparable to the US
elderly population with respect to age, sex, and socioeconomic
measures (education and poverty level). However, cancer
mortality rates are slightly lower in the SEER-Medicare cohort
as compared with the total US population [9].
The SEER registry has been found to capture almost all
(97%) incident cancer cases based on comparisons with
detailed reviews of hospital, pathology, and radiation oncology
records [10, 11]. Medicare administrative data includes
information on demographics, Medicare enrollment, and
outpatient and inpatient claims. This includes part A
coverage for inpatient care, skilled nursing facilities, home
health and hospice. Part B Medicare covers outpatient care,
to which 95% of Medicare beneficiaries subscribe. About
97% of all US adults age 65 years and older have Medicare
as their primary insurer [9]. The combination of SEER and
Medicare data together has been shown to be highly
complete in determining which treatments a patient has
received [12, 13].
The observation period for study inclusion was
defined as 1 year before cancer diagnosis (in order to
capture comorbid conditions) until 1 month after initial
chemotherapy administration. We excluded those who
did not receive chemotherapy within 11 months after
cancer diagnosis. The Committee for the Protection of
Human Subjects at the University of California Los
Angeles approved this study.
Study population
We included subjects with breast, lung, prostate, and
colorectal cancer, diagnosed from (1994–2005), who
received chemotherapy within 11 months of their diagnosis.
We excluded those with in situ carcinoma or unknown
cancer stage, those eligible for Medicare coverage due to
disability or end-stage renal disease, and individuals for
whom Medicare claims data would not fully capture the
health care services they received: (1) not enrolled in both
Medicare parts A or B for ≥1 month during study period,
(2) enrolled in Medicare health maintenance organization
(HMO). Patients for whom the chemotherapy agents could
not be identified—patients with a chemotherapy adminis-
tration code but no claims for individual drugs or those
receiving inpatient treatment only—were also excluded.
To allow sufficient follow-up, we excluded those who
died within 28 days of initial chemotherapy administration
unless they were hospitalized for FN prior to death. Finally,
subjects who received G-CSF within 7 days of chemother-
apy administration were excluded since this would alter
their baseline risk of FN. Prophylactic antibiotic use to
prevent FN use could not be evaluated within the dataset.
Predictor variables
Cancer stage was evaluated as a potential risk factor for FN
using AJCC stage reported in SEER (stage I, II, III, and IV) for
breast, lung, and colon cancer. After 1993, within the SEER
dataset, prostate cancer was classified simply as 1 for local/
regional disease and 4 for advanced disease. We examined
patient demographic data from the Patient Entitlement and
Diagnosis Summary File (PEDSF), including age (5 year
intervals: 65–69, 70–74, 75–79, 80–84, 85 years and older),
sex, and race/ethnicity (white, black, Latino, Asian, other).
Receipt of chemotherapy, as previously described [14],
was identified by ICD-9 codes and J codes. The following
chemotherapy agents were classified as myelosuppressive
based upon a significant association with FN (p<0.05 for
Chi square): carboplatin, cisplatin, cladribine, etoposide,
floxuridine, irinotecan, paclitaxel, pentostatin, streptozocin,
vinblastine, vincristine, and vinorelbine.
Time between chemotherapy treatments (chemotherapy
interval) was estimated using the time between the first four
claims and coded as 1 (0–7 days), 2 (8-14), 3 (15–21), or
4 weeks (22–42). Subjects with variation in the length of
chemotherapy intervals were classified by the initial interval.
Subjects who had only one treatment were coded as “no
interval.” Time from diagnosis to initial administration of
chemotherapywas classified as less than 1month, 1–3months,
and greater than 3 months.
Comorbid conditions
Since burden of illness has been shown to affect both
cancer treatment [15, 16] and mortality [17], we included
unweighted count of comorbid conditions in our model
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using conditions contained in the Charlson Comorbidity
Index [18–20]. We considered a condition present if one
inpatient or two outpatient claims at least 1 month apart
included diagnostic codes in the 12 months prior to cancer
diagnosis [19, 21]. Because individual conditions may be
independent predictors of neutropenic events [1, 22], we
also tested the association of FN with the individual
conditions comprising the comorbidity index: myocardial
infarction, congestive heart failure, peripheral vascular
disease, other cardiovascular disease, dementia, chronic
pulmonary disease, rheumatologic disease, peptic ulcer
disease, liver disease, diabetes, paralysis, renal disease,
and acquired immunodeficiency syndrome.
Defining febrile neutropenia
The outcome was limited to the first cycle of chemotherapy
as more than 50% of episode of FN occur at this time and
decisions to use prophylactic growth factor should be made
before initiation of treatment [23, 24]. Also, chemotherapy
regimens are often modified if complications occur after the
first cycle of treatment. To ensure we examined FN
associated with the first cycle only and not subsequent
cycles, we limited the occurrence of FN to within 28 days
of the first chemotherapy administration. Medicare claims
do not have a specific code for FN, so we defined our
outcome variable as any of the following admission
diagnoses; neutropenia (ICD-9 288.0), fever of unknown
origin (ICD-9 780.6), or various infectious complications
(Appendix A). We also performed sensitivity analyses
using hospitalization with neutropenia (288.0) alone as a
narrower definition of FN.
Statistical analysis
We first randomly split the sample into a “training set” and a
“validation set” with two thirds of the sample included in the
training set and one third of the sample included in the
validation set. We examined the bivariate relationship of
demographic and clinical characteristics with febrile neutro-
penia using χ2 for categorical variables and t tests for
continuous variables. We used logistic regression to estimate
the association of the predictor variables with febrile
neutropenia. We used both forward and backward stepwise
selection methods to identify the best predictors for the final
model with p=0.10 for inclusion in the model. All two-way
interaction terms were also tested in the model.
We then created a prediction model using the beta
coefficients from the logistic regression. To simplify the
model, we multiplied the regression coefficients by a
common multiplying factor (10) and rounded to the nearest
integer [25]. The points assigned to each predictor ranged
from −13 to 6.
Performance of the risk-stratification system in the training
and validation set was quantified and compared using the
receiver operating characteristic analysis [26]. The predictive
accuracy of the model to identify patients at high risk of
developing FN was estimated using the C-statistic, which
ranges from 0.5, indicating a model that performs no better
than chance alone, to 1.0, indicating perfect prediction [27].
We also calculated positive and negative predictive values
for the ability of the model to evaluate a risk of FN greater
than 10%.
Results
The final sample included 86,693 subjects, from an initial
SEER-Medicare sample of 1,717,478 patients with breast,
lung, prostate, and colorectal cancer. Subjects were exclud-
ed because they were not diagnosed between 1994–2005
(N=490,106), were Medicare-eligible due to disability or
end-stage renal disease (N=97,590), were enrolled in
managed care, not eligible for Medicare A and B, or
disenrolled from Medicare for 1 or more months (N=
390,302), did not receive chemotherapy within 11 months of
diagnosis (N=320,689), were missing specific chemotherapy
agents (N=313,333) received G-CSF within 7 days of
chemotherapy (N=1,269), had in situ cancer or unknown
stage at time of diagnosis (N=5,198), or had unknown date
of diagnosis (N=11,347). We also excluded 681 men with
breast cancer.
Patient characteristics are presented in Table 1. Chemo-
therapy regimens varied greatly between cancer types.
Lung cancer was more commonly associated with comor-
bid conditions. The outcome variable (FN) also varied
significantly between cancer sub-types with the most
episodes of FN in the first cycle in subjects with lung
cancer (10.2%). The initial total sample was divided
randomly into the training sample (N=58,053) and valida-
tion sample (N=28,910). There were no significant differ-
ences in patient, disease, or treatment characteristics
between the two samples.
In bivariate analysis across all tumor types using the
training dataset, younger age, female sex and white race
were the only demographic characteristics correlated with
the outcome (Table 2). Patients with lung and colon cancer
diagnosis had an increased risk of FN while patients with
prostate cancer diagnosis had markedly decreased risk
of FN as compared with a breast cancer diagnosis. An
increasing number of comorbid conditions were also
associated with and increasing risk of FN. Being diagnosed
with stage II or greater cancer was associated with
increased risk of FN. In addition, having a shorter time
from diagnosis to initiation of chemotherapy and use of any
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Table 1 Patient characteristics according to type of cancer
Cancer type
Characteristic Breast Lung Colorectal Prostate P value
N 14,608 14,711 15,098 42,546
Female (%) 100 50.6 52.8 0 <0.001
Race (%) <0.001
White 85.0 86.8 85.1 81.3
Black 7.8 6.6 6.7 9.1
Latino 3.5 2.4 3.4 4.6
Asian 3.4 4.0 4.6 4.7
Other 0.2 0.2 0.2 0.3
Age at diagnosis (%) <0.001
65–69 years 29.9 23.6 19.0 14.9
70–74 years 34.7 34.7 30.4 29.0
75–79 years 23.0 26.8 28.8 29.5
80–84 years 9.3 11.6 16.2 17.7
85+ years 3.1 3.3 5.6 9.0
Stage at diagnosis (%) <0.001
1 21.8 17.8 4.7 93.7
2 54.6 6.2 26.2 0
3 16.1 44.5 51.5 0
4 7.4 31.5 17.6 6.3
Hematologic disorder (%) 15.4 18.9 31.9 18.2 <0.001
Cardiovascular disease (%) 12.6 20.7 17.1 19.6 <0.001
Congestive heart failure (%) 5.7 9.4 8.1 8.6 <0.001
Peripheral vascular disease (%) 5.6 10.7 6.7 7.3 <0.001
Chronic pulmonary disease (%) 13.8 39.8 15.9 17.4 <0.001
Previous malignancy (%) 12.8 19.3 15.0 4.8 <0.001
Diabetes mellitus (%) 18.4 18.4 20.9 20.2 <0.001
Chronic renal disease (%) 1.3 2.0 1.7 3.0 <0.001
Liver disease (%) 0.4 0.5 0.5 0.4 0.35
Acquired immunodeficiency syndrome (%) 0.04 0.05 0.02 0.05 0.17
Dementia (%) 0.4 0.5 0.3 1.0 <0.001
Peptic ulcer disease (%) 1.6 2.7 3.6 2.3 <0.001
Paralysis (%) 0.06 0.02 0.04 0.04 0.39
Rheumatologic disease (%) 3.2 3.4 2.5 2.0 <0.001
Total number of comorbid conditions <0.001
0 49.2 31.6 38.2 44.9
1 27.7 28.7 27.6 27.5
2 12.7 18.9 17.5 14.4
3 or more 10.4 20.9 16.7 13.1
Months from diagnosis to first chemotherapy <0.001
<1 month 5.4 13.6 3.1 20.7
1-3 months 55.2 54.5 58.4 53.7
More than 3 months 39.4 31.8 38.5 25.5
Chemotherapy interval–first (%) <0.001
No interval 24.5 21.0 24.2 71.5
1 week 19.4 32.0 38.5 0.7
2 weeks 11.5 10.4 13.8 0.6
3 weeks 32.2 20.3 4.5 0.8
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myelosuppressive chemotherapy agent were associated
with FN.
In multivariate analysis, the independent predictors of
FN were cancer type, cancer stage (stage 2 or greater), an
increasing number of comorbid conditions, and less than
1 month from time of diagnosis to initiation of chemother-
apy (Table 3). Predictor variables and overall performance
of the models were similar when looking at the more
restrictive definition of FN (ICD-9 diagnosis of neutropenia
only) and the less restrictive definition (ICD-9 diagnosis
of neutropenia, infection, or fever; data not shown). The
C-statistic for was 0.75 for both the training and validation
datasets. We tested all 2-way interaction terms, a few of
which were statistically significant, but had almost no
effect on the predictive value of the model. Thus, we
chose to exclude the interaction terms from the model
for the sake of simplicity and ease of calculating a FN
risk score.
The point values for the clinical prediction model were
created from the multivariate model of the training dataset
(Table 3). Correlation between the predicted probability
from the multivariate model and the prediction model score
was high (0.93). For each patient, individual risk score
values were summed to create a total risk score. Maximum
possible score was 19, and highest reached within the
sample was 19.
Those with higher risk scores had a higher predicted and
observed risk of FN in the first 28 days (Table 4). Among
those with a score of 0 or less, the predicted risk of FN in
the first 28 days was 1.6%, and the observed risk was 1.6%
in the validation dataset. In contrast, those with a risk score
of 13 or higher had a predicted risk of 15.0% and an
observed risk of 15.5% in the validation dataset. Similar
results were found in the training dataset.
A cutoff of 10 points (scoreQ10) on the FN risk score
was associated with a predicted FN risk of greater than
10%. Using this cutoff, the sensitivity of the model was
24% and specificity of 93%. The positive predictive value
was 12% and negative predictive value 97%.
Discussion
In this study, we created and internally validated a clinical
prediction model for development of FN in the first cycle of
chemotherapy among elderly patients with four common
malignancies. With increasingly aggressive efforts to treat
malignancies within this population, themodel has the potential
to help clinicians identify those patients at greatest risk of FN
prior to initiation of myelosuppressive chemotherapy. Efforts
were made to maintain the simplicity of the model by keeping
myelosuppressive chemotherapy as a dichotomous variable and
using a total number of comorbid conditions, to assure that it
could be easily used with information readily available within
the clinic setting. Ultimately, the model provided moderate
predictive power to identify patients at higher risk of
developing FN.
To our knowledge, a clinical prediction model of this
nature has not previously been published. Given the difficulty
in identifying a high-risk patient population, past studies have
attempted to find predictors of FN and have identified patient
specific factors as well as therapy and disease-related effects.
Similar to previous studies, we found that increased risk of FN
was associated with more advanced stage at diagnosis and
comorbid conditions [24, 28]. Previous studies have found
that persons older than 65 years have a higher risk of FN
than those who are younger [24, 29]. Although we expected
that the risk might increase with increasing age in the elderly,
we did not find an association between age and FN among a
sample of persons older than 65 years. Although the reason
for this finding is not clear from our analysis, it may reflect
the use of lower doses or less aggressive chemotherapy
regimens for older persons. Alternatively, the risk of FN may
be greater for those 65 years and older compared with those
under age 65 years, but FN risk may not vary substantially
among those older than 65 years.
A recent national cohort of prospectively enrolled
patients undergoing chemotherapy found that neutropenic
complications, defined as an absolute neutrophil count less
than 500 or infection, were associated with anthracycline
Table 1 (continued)
Cancer type
Characteristic Breast Lung Colorectal Prostate P value
4 weeks 12.3 16.1 18.7 26.4
Number of myelosuppressive drugs (%) <0.001
0 93.9 8.3 92.4 62.0
1 5.1 34.4 7.1 28.0
2 1.0 57.0 0.5 10.0
3 or more 0.0 0.3 0.0 0.0
Febrile neutropenia (%) 4.1 10.2 5.5 1.0 <0.001
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chemotherapy regimens, pre-treatment cytopenia, prior
chemotherapy, low performance status, elevated blood urea
nitrogen, and elevated alkaline phosphatase [30, 31]. We
found a number of other agents in addition to anthracycline
drugs associated with FN, which suggests that the elderly
may have a different risk of FN with these agents than
younger patients. However, a recent publication which
summarized available clinical data noted a greater than 10%
incidence of febrile neutropenia for numerous non-
anthracycline based chemotherapeutic regimens [6]. We
Table 2 Bivariate correlates of febrile neutropenia in the first cycle of chemotherapy
Characteristic No FN FN OR (95% CI) P value
N 55,797 2,256
Cancer type (%)
Breast 16.9 17.5 Reference
Lung 15.8 44.3 2.71 (2.40–3.05) <0.001
Colon 16.9 25.0 1.44 (1.26–1.64) <0.001
Prostate 50.4 13.2 0.25 (0.22–0.30) <0.001
Female (%) 33.6 53.3 2.25 (2.07–2.45)
Race (%)
White 83.5 82.8 Reference
Black 8.0 9.0 1.12 (0.97–1.30) 0.12
Latino 3.8 3.4 0.90 (0.71–1.13) 0.36
Asian 4.4 4.6 1.06 (0.87–1.29) 0.56
Age at diagnosis (%)
65-69 19.6 21.6 Reference
70-74 31.1 32.5 0.94 (0.84–1.06) 0.35
75-79 27.8 27.6 0.89 (0.79–1.0) 0.08
80-84 15.0 13.1 0.79(0.68–0.91) 0.002
85+ 6.5 5.1 0.71 (0.58–0.88) 0.0001
Stage at diagnosis (%)
1 54.7 21.9 Reference
2 14.5 18.1 3.11 (2.72–3.55) <0.001
3 18.6 36.6 4.89 (4.37–5.48) <0.001
4 12.2 23.4 4.78 (4.21–5.41) <0.001
Total number of Comorbid Conditions (%)
0 48.0 36.3 Reference
1 21.9 22.1 1.27 (1.14–1.42) <0.001
2 13.2 14.9 1.67 (1.48–1.89) <0.001
3 or more 17.0 26.7 2.25 (2.01–2.53) <0.001
Months from diagnosis to chemotherapy (%)
<1 month 14.0 15.0 Reference
1–3 months 54.9 55.2 0.94 (0.83–1.06) 0.28
More than 3 months 31.2 29.8 0.89 (0.78–1.02) 0.08
Chemotherapy interval (%)
No Interval 47.4 31.4 0.61 (0.54–0.68) <0.001
1 week 15.5 20.0 1.19 (1.04–1.35) 0.009
2 weeks 6.2 12.1 1.78 (1.53–2.07) <0.001
3 weeks 10.0 13.8 1.28 (1.10–1.47) 0.001
4 weeks 20.8 22.6 Reference
Number of myelosuppressive drugs
0 65.5 50.7 Reference
1 15.6 22.6 1.88 (1.64–2.15) <0.001
2 or more 18.9 26.7 1.83 (1.61–2.07) <0.001
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suspect that our extensive database also allowed us to
identify other agents not normally captured in smaller
studies. Our study lacked some of the clinical detail
included in the prospective cohort; however, it is based
upon a population-based sample and thus is less subject to
selection bias that may result when practices and patients
have to agree to participate.
Cancer type was also associated with FN in our
multivariate analysis and was included in the prediction
model. Numerous past studies that have evaluated risk
factors for FN have focused on a single cancer type such as
NHL and breast cancer [22]. Patients with hematologic
malignancies have been demonstrated to have an increased
risk of FN [6, 22]. The prospective study previously
outlined did include a variety of solid tumor diagnosis,
but they were not noted to be associated with FN in
published results [31]. We suspect that the influence of
cancer type on episodes of FN is related to both individual
patient factors, such as overall health and performance
status not captured with our comorbid illness score, as well
as difference in treatment regimens that were not captured
by our chemotherapy variables.
While the chemotherapy interval was not associated with
FN, receiving chemotherapy within 1 month (as compared
Table 3 Multiple logistic regression predicting febrile neutropenia in the first cycle of chemotherapy (N=63,033)
Predictor (reference) Odds ratio P value 95% CI Prediction model points
Cancer type (breast cancer)
Lung cancer 2.01 <0.001 1.65–2.44 7
Colon cancer 1.26 0.001 1.09–1.45 2
Prostate cancer 0.27 <0.001 0.22–0.33 −13
Stage at diagnosis (stage 1)
Stage 2 1.29 0.003 1.09–1.53 3
Stage 3 1.38 <0.001 1.19–1.60 3
Stage 4 1.57 <0.001 1.35–1.83 5
Time from diagnosis to first chemotherapy treatment (<1 months)
1–3 month 0.70 <0.001 0.62–0.80 −4
>3 month 0.63 <0.001 0.55–0.73 −5
1 or more myelosuppressive chemotherapy agents
(chemotherapy with low myelosuppressive potential)
1.11 0.19 0.94–1.32 1
Comorbid conditions at diagnosis
1 1.13 0.02 1.02–1.28 1
2 1.39 <0.001 1.22–1.57 3
3 1.81 <0.001 1.61–2.04 6
Variables tested but excluded because not statistically significant: age, female sex, chemotherapy interval, race/ethnicity. Model was tested on
training dataset (N=63,033)
Table 4 Observed and predicted proportion of patients with febrile neutropenia (FN) in the first cycle by prediction score in the derivation and
validation datasets
Training dataset Validation dataset
Score N Observed FN, % Predicted FN, % N Observed FN, % Predicted FN, %
0 or lower 37,003 1.6 1.6 18,254 1.6 1.6
1–3 7,055 5.2 5.0 3,543 5.4 5.0
4–6 4,365 7.7 6.6 2,285 6.5 6.6
7–9 5,354 8.6 8.6 2,675 8.3 8.6
10–12 2,443 11.9 11.2 1,241 10.0 11.2
13 or higher 1,833 12.8 15.0 912 15.5 15.0
Overall 58,053 3.9 3.9 28,910 3.9 3.9
The observed FN rate is the actual proportion of subjects who had FN in the sample. The predicted FN rate is the average predicted risk of FN
based on the logistic regression model of FN that including the following covariates: cancer type, stage1 or more myelosuppressive
chemotherapeutic agents, comorbid conditions (cumulative number: 1, 2, 3) and time from cancer diagnosis to chemotherapy treatment
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with 1–3 months or >3 months) of diagnosis was associated
with a higher risk of FN. To our knowledge, timing of
chemotherapy initiation has not been examined in past
studies as a risk factor for development of FN. Although we
do not have any supporting evidence, we suspect that
timing of chemotherapy initiation may be a reflection of
disease severity (i.e., more rapid therapy for more aggres-
sive disease) or a proxy for patient-related factors that
influence the choice or intensity of chemotherapy regimens.
It is important to note that the current study only
identified episodes of FN in the first 28 days in order to
approximate the first cycle of chemotherapy. We limited our
prediction model to the first cycle because clinicians often
make changes to the chemotherapy dose based upon
patients' experience in the first cycle, and our dataset would
not capture these changes. In addition, the decision to use
G-CSF should ideally occur at the start of the first cycle
since that is when half or more of the FN episodes occur
and therefore should be based upon the data available to the
clinician at that time [23, 24].
Given that approximately 50% of episodes of FN occur
after initial chemotherapy cycle [30], we chose FN risk of
10% in the study as cutoff for our clinical prediction rule.
This cutoff is based on the assumption that those with risk
greater than 10% after initial cycle are similar to the
population with cumulative risk greater than 20% across all
cycles of chemotherapy. If the prediction rule is utilized
across all four malignancies, any patient with a prediction
score of 10 or greater would have 10% or greater predicted
risk of developing FN with the initial chemotherapy cycle
and should be considered for prophylactic growth factor
administration.
This study has a number of limitations common to
analysis of administrative datasets [32]. We identified
chemotherapy through Medicare claims which do not
accurately capture dose, which may be especially important
in an elderly population where physicians may be more apt
to reduce dose to avoid toxicity. Claims also lack clinical
data, such as neutrophil count or functional status, which
have been shown to be predictive of FN.
Because no specific ICD-9 codes exist for FN, we
defined FN as a hospitalization for fever, infection, or
neutropenia immediately following use of chemotherapy.
Chen-Hardee used SEER-Medicare data and chart reviews
to study FN in patients with non-Hodgkin's lymphoma [33].
With chart review data as the comparison, they found the
ICD-9 code for neutropenia (288.0) from the Medicare data
had 80% sensitivity for FN. Our definition of FN is likely
more sensitive, but may misclassify others who have
infections without neutropenia. However, the definition of
FN did not appear to bias our estimates of the risk of FN, as
the results were similar when the definition of FN was
varied in a sensitivity analysis.
Despite these limitations, the current study provides
important information and a potentially useful tool for
clinicians treating elderly patients with chemotherapy. The
clinical prediction model can easily be used with available
data prior to initiation of chemotherapy. Ongoing efforts
should be made with prospective cohorts with more
detailed clinical data to improve the accuracy of prediction
model. Specifically, laboratory data, performance status,
and more detailed information on chemotherapy dosing will
likely be valuable components to a final model. Before
our model is used in clinical practice, our current
prediction model should be tested in other cohorts to
examine its performance and clarify its overall utility.
Ultimately, implementation of an accurate prediction
model into clinical practice would help further define
the role of G-CSF on an individual patient basis and
improve the appropriate use of growth factors to prevent
FN after chemotherapy use.
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Appendix A
ICD-9 codes used to define outcome variable. Final
analysis included any admission with any of the following
ICD-9 codes as reason for admission.
1. Neutropenia, 288.0 (neutropenia); 288.9 (unspecified
disease of WBC)
2. Fever, 780.6 (general); 780.7 (malaise, fatigue)
3. Shock, 785.5x
4. Infection, 000.1–139.8 (coding for all specificmicrobiology)
5. Site specific infection codes:
(a) CNS:
i. Encephalitis/Meningitis, 320–326
(b) CV:
i. Rheumatic fever, 390–392
ii. Pericarditis, 420
iii. Endocarditis, 421
iv. Mycocarditis, 422
(c) Pulmonary:
i. Acute respiratory infections, 460–466
ii. Influenza/PNA, 480–487
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(d) GI:
i. Appendicitis, 540–543
ii. Gastritis, 535
iii. Peritonitis, 567
(e) GU:
i. Pyelonephritis, 590
ii. Cystitis, 595
iii. Urethritis, 597
iv. UTI, 599.0
(f) Skin:
i. Skin/Soft Tissue, 680–686
6. Symptoms
(a) Dyspnea/respiratory abnormality, 786.0–786.9
(b) Nausea/vomiting 787.0
(c) Abdominal pain 789
(d) Diarrhea 787.91
(e) Urinary frequency 788.4
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